UBS Upgrades Argenx Stock on Strong Vyvgart Sales Forecast

Investment bank UBS has upgraded its rating on pharmaceutical company Argenx, citing robust market potential for its drug Vyvgart. Analysts predict the medication could reach $20 billion in peak annual sales, driving optimism around the company's financial outlook.